Antibody responses to α-Gal in African children vary with age and site and are associated with malaria protection. by Aguilar, Ruth et al.
LSHTM Research Online
Aguilar, Ruth; Ubillos, Itziar; Vidal, Marta; Balanza, Núria; Crespo, Núria; Jiménez, Alfons; Nhab-
omba, Augusto; Jairoce, Chenjerai; Dosoo, David; Gyan, Ben; +6 more... Ayestaran, Aintzane; Sanz,
Hèctor; Campo, Joseph J; Gómez-Pérez, Gloria P; Izquierdo, Luis; Dobaño, Carlota; (2018) Antibody
responses to -Gal in African children vary with age and site and are associated with malaria protection.
Scientific reports, 8 (1). 9999-. ISSN 2045-2322 DOI: https://doi.org/10.1038/s41598-018-28325-w
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4654769/
DOI: https://doi.org/10.1038/s41598-018-28325-w
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
1SCIEntIfIC REPORTS |  (2018) 8:9999  | DOI:10.1038/s41598-018-28325-w
www.nature.com/scientificreports
Antibody responses to α-Gal in 
African children vary with age and 
site and are associated with malaria 
protection
Ruth Aguilar1, Itziar Ubillos1, Marta Vidal1, Núria Balanza1, Núria Crespo1, Alfons Jiménez1,2, 
Augusto Nhabomba3, Chenjerai Jairoce3, David Dosoo4, Ben Gyan4, Aintzane Ayestaran1, 
Hèctor Sanz1, Joseph J. Campo1, Gloria P. Gómez-Pérez1, Luis Izquierdo  1 & Carlota Dobaño  1
Naturally-acquired antibody responses to malaria parasites are not only directed to protein antigens 
but also to carbohydrates on the surface of Plasmodium protozoa. Immunoglobulin M responses to 
α-galactose (α-Gal) (Galα1-3Galβ1-4GlcNAc-R)-containing glycoconjugates have been associated 
with protection from P. falciparum infection and, as a result, these molecules are under consideration 
as vaccine targets; however there are limited field studies in endemic populations. We assessed a wide 
breadth of isotype and subclass antibody response to α-Gal in children from Mozambique (South 
East Africa) and Ghana (West Africa) by quantitative suspension array technology. We showed that 
anti-α-Gal IgM, IgG and IgG1–4 levels vary mainly depending on the age of the child, and also differ in 
magnitude in the two sites. At an individual level, the intensity of malaria exposure to P. falciparum and 
maternally-transferred antibodies affected the magnitude of α-Gal responses. There was evidence for a 
possible protective role of anti-α-Gal IgG3 and IgG4 antibodies. However, the most consistent findings 
were that the magnitude of IgM responses to α-Gal was associated with protection against clinical 
malaria over a one-year follow up period, especially in the first months of life, while IgG levels correlated 
with malaria risk.
Carbohydrates have not classically been considered to be significantly involved in adaptive immune responses, 
mostly being described as T cell-independent antigens that fail to induce immunological memory and immuno-
globulin (Ig) class-switching1. However, studies of carbohydrate-based vaccines in mice have shown a dominant 
IgM response2 with some IgG production3. Since the early 1990s, naturally occurring glycoproteins4, glycolipids5, 
and even protein-free polysaccharides6 have been shown to be important components of the adaptive repertoire 
and, currently, polysaccharide-based conjugate vaccines are widely used to provide protective immunity against 
bacterial meningitis7. At present, there are no vaccines in use against complex human parasites, and there is a 
need to expand the pipeline of targets of protective immunity against malaria and other neglected diseases. The 
investigation of parasite glycosylation may provide new opportunities for the discovery of novel vaccine candi-
dates against such diseases8.
The immune response against the malaria parasite Plasmodium falciparum has been mainly assessed against 
protein antigens. However, besides glycosylphosphatidylinositol (GPI) anchors9, the immunogenicity of carbo-
hydrates allegedly located in the surface of this parasite is largely underappreciated since the parasite seems to 
have lost many of the genes required to elaborate complex carbohydrates10. Nevertheless, recent works showed 
the presence of precursors involved in glycoconjugate biosynthesis11,12 and identified new glycosylations in the 
parasite surface13–15. Some of these sugars modify important antigens in the fight against malaria, such as the cir-
cumsporozoite surface protein (CSP), which is the main component of the RTS,S vaccine16 and is O-fucosylated 
in malaria sporozoites. These post-translational modifications may alter protein antigenicity, being relevant for 
vaccine design.
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It was recently demonstrated that antibodies against the classical α-Gal (Galα1-3Galβ1-4GlcNAc-R) epitopes 
confer protection against Plasmodium spp. infection, reducing malaria transmission by Anopheles mosquitoes17. 
This study showed that levels of IgG and IgM against α-Gal increased with age, and that IgM responses correlated 
with malaria incidence and were associated with protection against the disease17. On the contrary, IgG responses 
to α-Gal did not correlate with malaria exposure and were neither associated with protection17. Remarkably, 
other works have also reported the reduction of antigenicity of blood stage parasitic proteins after α-galactosidase 
treatment18. However, specific α-galactose containing glycans have never been isolated or structurally character-
ized in the malaria parasite.
Anti-α-Gal antibodies19 are produced against α-Gal epitopes, which are not expressed by humans due to the 
inactivation of the α-1,3-galactosyltransferase (α-1,3GT) in ancestral anthropoid primates20. Thus, anti-α-Gal 
antibodies are largely produced in response to cross-reactive epitopes present in commensal bacteria or food21,22, 
being the most abundant natural antibody in humans, constituting 1–5% of circulating IgM and IgG in healthy 
adults21. Anti α-Gal antibodies may also be produced in response to infection by pathogens expressing α-Gal, 
like the Gram-negative bacteria Salmonella spp. or the protozoan parasite Trypanosoma spp22–25. In fact, it has 
been argued that the selective pressure that removed this glycan from humans was exerted by an infectious agent 
like a virus, bacteria or protozoan expressing α-Gal epitopes, or an immunologically cross-reactive carbohydrate 
structure21,26.
In this study we investigated the anti-α-Gal response in children living in malaria-endemic areas of 
Mozambique (South East Africa) and Ghana (West Africa) who participated in clinical trials of the RTS,S/AS0 
vaccine. We examined the effect of age, malaria transmission intensity (MTI) and other variables on anti-α-Gal 
IgM, IgG, IgG1, IgG2, IgG3 and IgG4 responses, and assessed their association with protection against clinical 
malaria and the factors affecting it.
Results
Pilot study of α-Gal IgG and IgM antibodies. IgM and IgG against α-Gal were first evaluated in children 
age 1–4 years from the RTS,S/AS02A phase 2b trial in Mozambique. Responses measured at the first visit (Month 
0 [M0]) increased with age by 1.27 MFIs/year for IgM and by 1.48 MFIs/year for IgG (Table 1 and Supplementary 
Fig. 1). We observed a trend of IgG levels starting lower and increasing faster in Ilha Josina (cohort 2, high MTI) 
than in Manhiça (cohort 1, low MTI), reaching higher levels at age 4 years in Ilha Josina (Supplementary Fig. 1), 
however this trend was not statistically supported in the regression model, as site and age did not show a signif-
icant interaction (Table 1). These results suggest that IgM and IgG to α-Gal rise with age, and levels of IgM and 
IgG to α-Gal do not differ between neighborhoods of different MTI, or between malaria cases and controls in this 
small pilot study (data not shown).
Pattern of α-Gal antibody isotypes and subclasses in African children. IgM, IgG and IgG1–4 against 
α-Gal were measured in children age ≤2 years from the RTS,S/AS01E phase 3 trial in Ghana and Mozambique, 
after confirming that vaccination did not have an effect on antibody response to α-Gal (Tables 2, 3 and S1). 
Thus, from here onwards, analyses were conducted regardless of vaccination group. IgM predominated over IgG 
responses. Among IgG subclasses, IgG1 and IgG2 tended to be higher than IgG3, and IgG4 was the lowest (Fig. 1). 
IgG, IgG1 and IgG2 were higher at the first study timepoint (M0) probably due to maternal transfer, and IgM was 
higher three months later (M3), reflecting continuous exposure to α-Gal.
Effect of age on α-Gal antibody responses. When comparing M0 α-Gal antibody levels between the 
age study groups, IgMs were higher in children (5–17 months old) than in infants (1.5–3 months old) (p < 0.001), 
whereas total IgGs were equal between them (p = 0.58) (Fig. 2). IgG1, IgG3 and IgG4 were higher in children 
and IgG2 in infants, although only IgG3 and IgG4 remained significant after adjusting by multiple comparisons 
(p < 0.001) (Fig. 2). When analyzing the effect of continuous age on IgM and IgG levels within each age cohort, 
IgM showed a strong increase in infants (11 × 107 MFIs/year) and a lower increase in children (3.77 MFIs/year) 
(Table 4 and Fig. 3). In contrast, IgG did not vary with age within the infants group, but increased 8.62 MFIs/year 
Coefficient Std. Error t value Pr(>|t|)
IgM
(Intercept) 3.72402 0.15238 24.439 <2e-16
Age 0.10476 0.04851 2.16 0.0358
Site (Manhiça) 0.13553 0.21321 0.636 0.528
Age-site (Manhiça) interaction −0.02768 0.06566 −0.422 0.6752
IgG
(Intercept) 3.48813 0.23936 14.573 <2e-16
Age 0.17339 0.07619 2.276 0.0274
Site (Manhiça) 0.2264 0.33492 0.676 0.5023
Age-site (Manhiça) interaction −0.06506 0.10315 −0.631 0.5312
Table 1. Regression models to assess the effect of age on anti-α-Gal antibody levels and interaction with site in 
children aged 1 to 4 years old from Manhiça and Ilha Josina. Data correspond to samples collected at baseline 
(M0) from children participants in the Mozambican RTS,S phase 2b clinical trial.
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within the children group (Table 4 and Fig. 3). These results suggest that IgM increases from birth towards older 
ages, while total IgG does not increase during the initial months of life but an increase is already detected at age 
>5 months old. These observations were corroborated by multivariable linear regression models, showing that 
M3 levels of all six anti-α-Gal Ig increased with age as continuous or categorical (Table 2), but when stratifying 
by age group, IgM increased with age only in infants, while in children increments were observed for IgG, IgG2 
and IgM (Table 3).
Furthermore, when comparing anti-α-Gal IgM, IgG and IgG1–4 subclass levels between time-points within 
each age group, we confirmed a significant increase of IgM from M0 to M3 in both age groups (p < 0.001) 
(Supplementary Fig. 2), being more marked in infants (also starting at lower basal levels) (Supplementary Fig. 3). 
IgG, IgG1, IgG2 and IgG3 levels decreased from M0 to M3 in infants (p < 0.001, p = 0.02, p < 0.001 and p = 0.01, 
respectively), and were recovered in children, with IgG levels being even higher at M3 than in M0 in this group 
(Supplementary Figs 2 and 3). This observation is compatible with a significant maternal transfer of anti-α-Gal 
IgG, IgG1, IgG2 and IgG3 to the newborn, corresponding to the levels measured in infants at M0, and a decay 
of these IgGs during the first months of life, evidenced by the lower M3 levels in infants. Overall, the increase of 
anti-α-Gal IgG and IgM levels in children compared to infants at M3 suggests a continued exposure to α-Gal.
Effect of MTI on α-Gal antibody responses. IgG, IgG1, IgG3 and IgG4 levels to α-Gal were signifi-
cantly higher in Manhiça (low MTI) than Kintampo (high MTI) (p < 0.001, p = 0.002, p < 0.001 and p < 0.001, 
respectively) (Fig. 4A). When stratifying by age cohort, IgM and IgG4 were higher in infants (1.5–3 months) from 
Manhiça compared to Kintampo (p = 0.003 and p = 0.042, respectively), and total IgG, IgG1 and IgG3 showed 
a trend in the same direction (p = 0.08, p = 0.09 and p = 0.08, respectively) (Fig. 4B). Similarly, IgG, IgG1, IgG2, 
IgG3 and IgG4 were higher in children from Manhiça compared to Kintampo (p = 0.003, p = 0.01, p = 0.01, 
p < 0.001 and p < 0.001, respectively), but IgM did not show differences in this age group (Fig. 4B). Multivariable 
linear regression models also showed that IgG, IgG1, IgG3, IgG4 and IgM levels were higher in Manhiça com-
pared to Kintampo (Table 2), but this was mostly for children, because when stratifying by age group, in infants 
only IgM was higher in Manhiça than Kintampo (Table 3).
Effect of baseline malaria exposure and maternal antibodies on α-Gal antibody responses. 
The intensity of exposure to P. falciparum at M0, as indicated by antibody surrogate markers, was positively asso-
ciated with anti-α-Gal IgM levels at M3 in multivariable linear regression models (Coeff [CI]: 10.6 [5.32; 16.13] 
Antibody
Age*
Age 
cohort Sex Site WAZ HAZ Hb
Exposure 
index
Maternal 
index
Prior 
episode† Seasonǂ Vaccine
IgG at 
M0
IgM at 
M0
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
IgG
4.16 
(3.31;5.02) 
<0.001
403.47 
(237.49; 
651.09) 
<0.001
−13.71 
(−45.39; 
36.34) 1
76.7 
(11.52; 
180) 
0.047
−17.01 
(−32.47;2) 
0.38
−4.84 
(−22.02; 
16.12) 1
−0.2 
(−15.32; 
17.62) 1
6.24 
(0.64; 
12.16) 
0.14
−7.33 
(−12.39; 
1.97) 
0.03
17.99 
(−43.6; 
146.87) 1
−10.38 
(−66.78; 
141.74) 1
3.12 
(−36.44; 
67.29) 1
449.62 
(328.11; 
605.61) 
<0.001
138.22 
(93.47; 
193.33) 
<0.001
IgG1
2.64 
(1.65;3.64) 
<0.001
189.97 
(84.24; 
356.36) 
<0.001
2.49 
(−36.25; 
64.75) 1
91.76 
(19.18; 
208.53) 
0.03
−6.95 
(−24.97; 
15.41) 1
−6.96 
(−24.32; 
14.39) 1
−1.56 
(−16.97; 
16.72) 1
2.07 
(−3.56; 
8.03) 1
−9.13 
(−15.43; 
−2.35) 
0.03
−20.31 
(−62.92; 
71.25) 1
26.21 
(−54.86; 
252.9) 1
−28.76 
(−56.76; 
17.38) 1
189.1 
(108.36; 
301.14) 
<0.001
75.7 
(38.54; 
122.82) 
<0.001
IgG2
3.15 
(2.2;4.11) 
<0.001
173.79 
(75.41; 
327.35) 
<0.001
−17.39 
(−48.12; 
31.52) 1
7.01 
(−33.26; 
71.6) 
0.78
−7.91 
(−25.31; 
13.53) 1
−9.31 
(−25.68; 
10.67) 1
−1.6 
(−16.44; 
15.87) 1
1.85 
(−3.48; 
7.47) 1
0.02 
(−5.72; 
6.11) 
0.99
18.53 
(−44.13; 
151.47) 1
2.8 
(−62.52; 
181.97) 1
−3.38 
(−40.82; 
57.75) 1
332.76 
(225.44; 
475.47) 
<0.001
70.85 
(35.43; 
115.53) 
<0.001
IgG3
0.84 
(0.6;1.08) 
<0.001
54.04 
(38.41; 
71.44) 
<0.001
−2.26 
(−13.52; 
10.48) 1
31.71 
(16.96; 
48.32) 
<0.001
0.22 
(−5.2; 
5.96) 1
2.72 
(−2.61; 
8.33) 1
−2.44 
(−6.62; 
1.92) 1
−0.06 
(−1.51; 
1.42) 1
−2.89 
(−4.56; 
−1.19) 
0.004
−12.81 
(−28.38; 
6.13) 1
−10.96 
(−31.68; 
16.05) 1
2.39 
(−10.03; 
16.54) 1
15.29 
(5.29; 
26.25) 
0.007
21.22 
(14.32; 
28.54) 
<0.001
IgG4
0.77 
(0.56;0.98) 
<0.001
43.15 
(29.89; 
57.77) 
<0.001
−3.69 
(−13.62; 
7.39) 1
23.74 
(11.18; 
37.72) 
<0.001
1.64 
(−3.26; 
6.79) 1
2.51 
(−2.23; 
7.49) 1
−2.71 
(−6.42; 
1.15) 
0.68
0.26 
(−1.04; 
1.57) 1
−2.98 
(−4.34; 
−1.6) 
<0.001
−11.52 
(−25.72; 
5.39) 
0.85
−14.58 
(−32.47; 
8.07) 
0.94
3.18 
(−8.03; 
15.77) 1
10.14 
(1.51; 
19.51) 
0.03
18.13 
(12.09; 
24.49) 
<0.001
IgM
4.3 
(3.56;5.05) 
<0.001
609.34 
(412.38; 
882) 
<0.001
−36.58 
(−58.33; 
−3.48) 
0.2
102.99 
(33.11; 
209.54) 
0.006
−21.63 
(−35.18; 
−5.24) 
0.07
4.85 
(−12.83; 
26.11) 1
−16.45 
(−28.11; 
−2.9) 
0.12
10.6 
(5.32; 
16.13) 
<0.001
−18.4 
(−23.63; 
−12.82) 
<0.001
−23.5 
(−61.42; 
51.67) 1
−57.25 
(−82.84; 
6.54) 
0.41
14.99 
(−26.58; 
80.09) 1
49.35 
(8.7; 
105.2) 
0.03
208.53 
(163.58; 
261.14) 
<0.001
Table 2. Factors affecting the anti-α-Gal response at month 3. Multivariable linear models including phase 3 
participants from both age groups and sites together. The coefficients indicate % change for a unit change in 
the predictor (95% confidence intervals [CI]). P-values are adjusted for multiple testing through Benjamini-
Hochberg and Holm; those significant are in bold. *Continous age in weeks. Age cohort (children vs infants). 
Sex (male vs female). Site (Manhiça vs Kintampo). WAZ (Weight-for-Age Z-score). HAZ (Height-for-Age 
Z-score). Hb (Baseline hemoglobin (g/dL). Exposure index (baseline anti-P. falciparum exposure IgM levels). 
Maternal index (baseline maternally transferred antibodies). †Malaria episode between month 0 and month 
3 (yes vs no). ǂMalaria transmission season at month 3 sample collection (low vs high). Vaccine (RTS,S vs 
comparator).
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p < 0.001) (Table 2). However, this effect disappeared when stratifying by age group (Table 3), probably because 
of the reduction in the sample size. Regarding IgG responses, P. falciparum exposure was negatively associated 
with anti-α-Gal IgG3 levels in children (−3.76 [−6.15; −1.32] p < 0.001) (Table 3). The models also showed 
a negative effect of P. falciparum maternally-transferred IgGs on anti-α-Gal IgG levels (−7.33 [−12.39; 1.97] 
p = 0.03), IgG1 (−9.13 [−15.43; 2.35] p = 0.03), IgG3 (−2.89 [−4.56; −1.19] p = 0.004), IgG4 (−2.98 [−4.34; 
Antibody
Age* Sex Site WAZ HAZ Hb
Exposure 
index
Maternal 
index
Prior 
episode† Seasonǂ vaccine IgG at M0
IgM at 
M0
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Infants
IgG
13.89 
(−0.69; 
30.61) 
0.31
−22.34 
(−46.73; 
13.21) 
0.93
44.7 
(−1.77; 
113.16) 
0.31
−5.4 
(−21.29; 
13.7) 1
4.39 
(−11.17; 
22.67) 1
−0.73 
(−15.88; 
17.14) 
0.93
−0.31 
(−5.94; 
5.66) 1
−4.08 
(−10.61; 
2.92) 0.73
0.12 
(−48.12; 
93.23) 1
96.96 
(6.32; 
264.89) 
0.19
19.03 
(−20.16; 
77.48) 
0.95
235.96 
(150.48; 
350.62) 
<0.001
−5.88 
(−30.61; 
27.67) 1
IgG1
7.63 
(−11.33; 
30.65) 1
−3.34 
(−43.13; 
64.27) 1
56.1 
(−9.3; 
168.67) 
0.43
−3.6 
(−25.45; 
24.65) 1
−4.63 
(−23.92; 
19.55) 1
−18.33 
(−34.97; 
2.57) 0.49
0.66 
(−7.18; 
9.17) 1
−9.69 
(−18.03; 
−0.49) 
0.16
−51.53 
(−80.44; 
20.07) 
0.47
115.22 
(−9.57; 
412.24) 
0.41
−35.96 
(−63.16; 
11.31) 
0.68
−12.27 
(−47.94; 
47.86) 1
−1.8 
(−35.86; 
50.32) 1
IgG2
−7.24 
(−20.69; 
8.47) 1
−4.21 
(−36.69; 
44.93) 1
−26.77 
(−51.99; 
11.71) 
0.43
−6.47 
(−23.15; 
13.83) 1
−4 
(−19.18; 
14.03) 1
12.06 
(−5.86; 
33.39) 
0.72
−3.94 
(−9.63; 
2.1) 1
0.62 
(−6.87; 
8.71) 1
113.08 
(1.23; 
348.53) 
0.26
67.49 
(−15.07; 
230.3) 
0.54
33.11 
(−13.8; 
105.54) 
0.86
114.92 
(45.65; 
217.14) 
<0.001
−27.37 
(−47.97; 
1.38) 0.24
IgG3
0.52 
|(−1.09; 
2.16) 1
3.44 
(−0.98; 
8.06) 0.64
4.37 
(−0.23; 
9.18) 0.31
0.03 
(−2.09; 
2.19) 1
1.35 
(−0.53; 
3.25) 0.95
−1.5 
(−3.36; 
0.39) 0.58
−0.14 
(−0.81; 
0.54) 1
−0.37 
(−1.18; 
0.45) 0.75
−2.87 
(−10; 
4.82) 0.90
9.43 (1.91; 
17.5) 0.08
2.43 
(−2.21; 
7.29) 0.92
2.59 
(−1.75; 
7.12) 0.73
−0.63 
(−4.09; 
2.96) 1
IgG4
0.88 
(−0.24; 
2.02) 0.49
−1.08 
(−4.08; 
2.01) 1
2.6 
(−0.59; 
5.9) 0.43
−1.19 
(−2.64; 
0.28) 0.67
0.08 
(−1.23; 
1.41) 1
−0.51 
(−1.84; 
0.83) 0.9
0.02 
(−0.45; 
0.49) 1
−0.77 
(−1.32; 
−0.22) 
0.03
−5.25 
(−10.08; 
−0.15) 
0.26
1.07 
(−3.97; 
6.37) 1
2.26 
(−0.99; 
5.61) 0.86
0.23 
(−2.77; 
3.33) 1
2.67 (0.21; 
5.19) 0.17
IgM
49.05 
(25.69; 
76.76) 
<0.001
−50.77 
(−69.89; 
−19.51) 
0.03
278.48 
(138.23; 
501.3) 
<0.001
−16.91 
(−34.95; 
6.13) 0.68
2.98 
(−17.12; 
27.95) 1
−16.08 
(−32.63; 
4.53) 0.58
5.17 
(−2.67; 
13.64) 1
−16.68 
(−23.74; 
−8.98) 
<0.001
−48.17 
(−78.36; 
24.15) 
0.47
7.17 
(−53.99; 
149.65) 1
31.29 
(−23.14; 
124.27) 
0.95
49.53 
(−8.99; 
145.69) 
0.44
119.91 
(50.3; 
221.78) 
<0.001
Children
Antibody
Age* Sex Site WAZ HAZ Hb Exposure index
Maternal 
index
Prior 
episode† Vaccine IgG at M0
IgM at 
M0
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
Coef(CI) 
p-val
IgG
4.46 (2.15; 
6.82) 
0.001
21.57 
(−44.06; 
164.22) 1
197.26 
(41.24; 
525.65) 
0.02
−11.62 
(−36.6; 
23.2) 1
−27.07 
(−48.29; 
2.87) 0.43
31.26 
(3.14; 
67.04) 
0.14
−2.23 
(−10.28; 
6.55) 1
−7.33 
(−17.6; 
4.21) 0.78
2.96 
(−67.76; 
228.75) 1
−14.86 
(−62.48; 
93.21) 1
553.04 
(407.38; 
740.51) 
<0.001
643.92 
(247.07; 
1494.52) 
<0.001
IgG1 2.53 (0.1; 5.02) 0.12
26.8 
(−42.24; 
178.4) 1
196.13 
(39.09; 
530.48) 
0.02
2.21 
(−27.09; 
43.29) 1
−17.75 
(−42.21; 
17.07) 1
33.39 
(4.54; 
70.2) 0.13
−5.67 
(−13.48; 
2.83) 0.73
−4.46 
(−15.7; 
8.28) 0.93
5.06 
(−67.62; 
240.84) 1
−18.89 
(−64.64; 
86.05) 1
398.63 
(255.6; 
599.19) 
<0.001
226.21 
(39.11; 
664.94) 
0.02
IgG2
5.39 (2.83; 
8.02) 
<0.001
−12.98 
(−64.11; 
110.98) 1
118.5 
(−7.74; 
417.5) 
0.15
2.75 
(−29.53; 
49.81) 1
−23.1 
(−47.82; 
13.33) 
0.91
4.55 
(−20.37; 
37.25) 1
−2.87 
(−11.64; 
6.77) 1
−1.92 
(−12.69; 
10.18) 
0.93
−43.84 
(−83.92; 
96.14) 1
−29.48 
(−71.65; 
75.42) 1
491.83 
(312.64; 
748.81) 
<0.001
481.29 
(143.92; 
1285.23) 
<0.001
IgG3
0.01 
(−0.74; 
0.76) 0.98
−3.81 
(−24.22; 
22.09) 1
87.77 
(54.22; 
128.61) 
<0.001
5.94 
(−4.29; 
17.26) 1
1.14 
(−9.17; 
12.63) 1
3.87 
(−3.7; 
12.05) 
0.96
−3.76 
(−6.15; 
−1.32) 
<0.001
−3.76 
(−9.35; 
2.16) 0.78
−27.28 
(−48.73; 
3.14) 0.44
2.1 
(−20.62; 
31.32) 1
19.74 
(3.92; 
37.98) 
0.03
10.43 
(−15.58; 
44.46) 
0.93
IgG4
0.35 
(−0.33; 
1.03) 0.63
−2.5 
(−21.68; 
21.39) 1
64.9 
(36.16; 
99.71) 
<0.001
9.34 
(−0.26; 
19.88) 
0.34
3.1 
(−6.58; 
13.79) 1
1.4 
(−5.45; 
8.74) 1
−2.65 
(−4.91; 
−0.32) 
0.13
−3.99 
(−8.62; 
0.86) 0.51
−22.36 
(−43.77; 
7.22) 0.61
4.16 
(−17.34; 
31.23) 1
13.5 
(−0.56; 
29.55) 
0.06
7.65 
(−15.91; 
37.82) 
0.93
IgM 1.69 (0.61; 2.79) 0.01
12.46 
(−21.66; 
61.45) 1
35.76 
(−5.09; 
94.2) 0.15
−6.63 
(−20.01; 
8.99) 1
−8.23 
(−21.99; 
7.96) 1
13.11 
(1.06; 
26.59) 
0.14
−1.01 
(−4.9; 
3.03) 1
−6.73 
(−12.46; 
−0.62) 
0.19
−22.59 
(−54.82; 
32.63) 1
−3.92 
(−34.45; 
40.83) 1
36.13 
(10.01; 
68.47) 
0.02
183.54 
(101.56; 
298.87) 
<0.001
Table 3. Factors affecting the anti-α-Gal response at month 3 stratified by age group. Multivariable linear 
models including phase 3 participants from both sites stratifying by age group. The coefficients indicate % 
change for a unit change in the predictor (95% confidence intervals). P-values were adjusted for multiple 
comparisons through Benjamini-Hochberg and Holm; those significant are in bold. *Continous age in weeks. 
Age cohort (children vs infants). Sex (male vs female). Site (Manhiça vs Kintampo). WAZ (Weight-for-Age 
Z-score). HAZ (Height-for-Age Z-score). Hb (Baseline hemoglobin (g/dL). Exposure index (baseline anti-P. 
falciparum exposure IgM levels). Maternal index (baseline maternally transferred antibodies). †Malaria episode 
between month 0 and month 3 (yes vs no). ǂMalaria transmission season at month 3 sample collection (low vs 
high). Vaccine (RTS,S vs comparator).
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−1.6] p < 0.001) and IgM (−18.4 [−23.63; −12.82] p < 0.001) (Table 2), but when stratifying by age group, this 
effect only remained significant for IgM in infants (−16.68 [−23.74; −8.98] p < 0.001) (Table 3), probably due to 
the reduced sample size.
Effect of α-Gal antibodies in protection against clinical malaria. Anti-α-Gal IgM, IgG3 and IgG4 
levels at M3 were higher in those subjects who did not have a clinical malaria episode over one year of follow up 
(p = 0.002, p < 0.001 and p = 0.002, respectively) (Fig. 5A). When stratifying by age group, IgM was higher only 
in infants (p < 0.001), and IgG3 and IgG4 only in children (p = 0.001 and p = 0.004) who did not subsequently 
develop clinical malaria (Fig. 5B). When looking at differences between cases and controls stratifying by site (but 
not age) (Fig. 5C), IgM, IgG3 and IgG4 were borderline significantly higher only in non-malaria controls from 
Manhiça (p = 0.09 for all).
Figure 1. Antibody isotype and subclass responses to α-Gal by timepoint. Boxplots represent the median and 
interquartile ranges of IgM, IgG and IgG1–4 levels in infants and children from Manhiça and Kintampo (all 
together) participating in the RTS,S phase 3 trial, measured at the first recruitment visit (M0) and three months 
later (M3). Groups were compared through t-tests and p-values were adjusted for multiple comparisons through 
Benjamini-Hochberg and Holm (in parenthesis).
Figure 2. Antibody isotype and subclass responses to α-Gal by age group. Comparison of levels of IgM, IgG 
and IgG1–4 between infants (1.5–3 months old) and children (5–17 months old), both sites together. Data 
correspond to samples collected at recruitment (M0) from participants in the RTS,S phase 3 clinical trial. 
Boxplots represent the median and interquartile range. Groups were compared through t-tests and p-values 
were adjusted for multiple comparisons through Benjamini-Hochberg and Holm (in parenthesis).
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Logistic regression models were fitted including the covariates significantly associated to risk of clinical 
malaria, like being an infant, being immunized with a comparator vaccine, being from Kintampo, having had 
prior malaria episodes, and having higher M0 P. falciparum antibodies (indicative of malaria exposure and/
or maternal antibodies). Univariate models showed a protective association of anti-α-Gal IgM (OR [CI] 0.43 
[0.26; 0.68], p = 0.001), IgG3 (0.02 [0; 0.18], p < 0.001) and IgG4 (0.02 [0; 0.2], p = 0.001) with clinical malaria 
(Table 5). Stratifying by age group, anti-α-Gal IgM correlated with less risk of clinical malaria in infants (0.24 
[0.1–0.52], p < 0.001), and anti-α-Gal IgG3 (0.02 [0; 0.18], p = 0.002) and IgG4 (0.01 [0; 0.18], p = 0.003) in 
children (Table 5). Stratified by site, anti-α-Gal IgM had a protective role only in Manhiça (0.36 [0.15; 0.78], 
p = 0.055) (Supplementary Table 2). Finally, multivariable stepwise regression models adjusting by the potential 
cofounders revealed a significant association of anti-α-Gal IgM (0.29 [0.1; 0.77], p = 0.02) with lower risk of clin-
ical malaria in infants; and of anti-α-Gal IgG (7.99 [1.54; 58.03], p = 0.02) with higher risk of clinical malaria in 
children (Table 6).
Discusion
We have assessed the IgM, IgG and IgG1–4 responses to α-Gal in children of different ages from two different 
African countries. Results show that anti-α-Gal IgM and IgG responses vary mainly depending on the age of 
the child and the location, but other factors like level of malaria exposure and maternally-transferred antibodies 
also affect them. Importantly, our data indicates that the magnitude of IgM responses to α-Gal is associated to 
protection against malaria, especially in the first months of life, while IgG levels may correlate with malaria risk. 
Our findings also point towards a possible protective role of anti-α-Gal IgG3 and IgG4 that needs to be better 
addressed in larger studies. Since antibodies against α-Gal are usually measured in Caucasian adults, and prior 
data on their levels in childhood are incomplete or even inexistent in African children19,27,28, our study provides 
novel and relevant information on anti-α-Gal antibody responses that are putative targets of immunity against 
several infectious diseases.
First, we provide additional insight into the age pattern of serological responses to this glycan. The anti-α-Gal 
IgM response in infants age 1.5 to 3 months started at very low levels but showed a rapid increase during the first 
months of life, reaching higher levels than IgG. This result is similar to Hamanova et al.28 on European children, 
and suggests exposure to α-Gal in the neonate and maintenance of this exposure over time. However, our data 
show an earlier and faster increase of α-Gal antibodies in African children. Exposure to α-Gal originates in the 
neonate gut microbiota, which is influenced by the mode of delivery, the gestational age and the mother breast 
milk microbiota, which in turn is influenced by maternal health29–31. All these factors are expected to be different 
between Europeans and Africans. Moreover, recent studies show that there is a significant effect of geographical 
variations in human milk microbiota composition30,32. Thus, geographical differences in human milk microbiota 
and exposure to pathogenic microbes could explain the differences in the anti-α-Gal IgM responses between 
European and African infants, and potentially among African regions.
Coefficient Std. Error t value Pr(>|t|)
IgM
Infants
(Intercept) 3.6632 0.5562 6.587 1.83E-09
Age 8.0381 3.8208 2.104 0.0378
Manhiça 0.3859 0.9327 0.414 0.6799
Age-site (Manhiça) interaction −1.2675 5.6345 −0.225 0.8225
IgG
(Intercept) 5.969 0.4852 12.302 <2e-16
Age −3.1377 3.3335 −0.941 0.349
Manhiça −0.2149 0.8137 −0.264 0.792
Age-site (Manhiça) interaction 3.1261 4.9158 0.636 0.526
IgM
Children
(Intercept) 6.0856 0.2015 30.201 <2e-16
Age 0.5762 0.2035 2.831 0.00584
Manhiça −0.2545 0.2701 −0.942 0.34871
Age-site (Manhiça) interaction 0.3149 0.2721 1.158 0.25042
IgG
(Intercept) 4.5273 0.3568 12.689 <2e-16
Age 0.9355 0.3604 2.596 0.0112
Manhiça 0.1022 0.4782 0.214 0.8313
Age-site (Manhiça) interaction 0.4787 0.4817 0.994 0.3233
Table 4. Regression models to assess the effect of age on anti-α-Gal antibody levels and interaction with site in 
infants (1.5–3 months old) and children (5–17 months old) from Manhiça and Kintampo. Data correspond to 
samples collected at baseline (M0) from participants in the RTS,S phase 3 clinical trial.
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Here, the α-Gal IgG response was already high in infants and did not increase during the first months of 
life. On the contrary, it tended to decrease, as evidenced when comparing Ig levels between M0 and M3 in this 
age group. On the other hand, in children (5 to 17 months old) IgG levels at M0 were similar to levels at M0 in 
infants, and increased towards M3. These results evidence a significant maternal transfer of anti-α-Gal IgG to 
the newborn, and a decay of this IgG during the first months of life, followed by an early and rapid increase. This 
suggests again a continued exposure to the glycan. These results are also similar to reports in European children28, 
although our data also suggest an earlier and faster increase of anti-α-Gal IgGs in African children compared to 
Europeans.
Overall, IgM and IgG to-α-Gal increased with age, however IgM reached higher levels than IgG, being the pre-
dominant response in children. This result is in agreement with previous works by Yilmaz et al. on subjects from 
3 months to 25 years of age in Mali17. In that study, this observation was interpreted as indicative of P. falciparum 
infection failing to induce class switch of the anti-α-Gal Ig antibody response. However a higher IgM response 
than its correspondent IgG response is also observed against other polysaccharidae antigens, such as Streptococcus 
pneumoniae33, suggesting that overall the rate of IgM/IgG switching is not as fast for polysaccharide antigens as 
for protein antigens.
Second, we analyzed the effect of malaria endemicity on the anti-α-Gal response. When comparing anti-α-Gal 
IgM and IgG responses between two areas of high (Kintampo) and low (Manhiça) MTI, we observed that both 
antibodies were higher at lower MTI. This may suggest that other exposures besides malaria may be more impor-
tant for their induction. It is known that, besides Plasmodium17, other pathogenic microbes express this glycan, 
like the protozoan parasites Leishmania spp. and Trypanosoma spp, the Gram-negative bacteria Salmonella spp., 
and some viruses22,23,34. Furthermore, common commensal bacteria in the midgut microbiota such as Escherichia 
spp., Klebsiella spp. and Serratia spp. also express α-Gal22. Also, exposure to different types of diet in both sites 
could be associated to the different anti-α-Gal responses. However, another possible explanation is that malaria 
infection affects the immune response to α-Gal in children living in high MTI. Previous studies show that P. 
falciparum malaria impairs the antibody response to polysaccharide vaccines (glycan antigens) but not responses 
to protein-based and whole parasite vaccines in children with malaria35. Young children (<3 years old) have 
immunologically immature spleens, mainly due to the still ongoing development of the marginal zone (MZ) B 
cell subset, which is the main responsible for the IgM response to polysaccharide antigens36,37. During malaria 
Figure 3. Distribution of anti-α-Gal IgG and IgM levels (log10MFI) as a function of age (continuous) stratified 
by age cohort and site (Manhiça and Kintampo). (A) Infants (1.5–3 months old); (B) children (5–17 months 
old). Scatter plot data correspond to samples collected at baseline (M0) from participants in the RTS,S phase 3 
clinical trial.
www.nature.com/scientificreports/
8SCIEntIfIC REPORTS |  (2018) 8:9999  | DOI:10.1038/s41598-018-28325-w
infection, the anatomy of the spleen becomes disorganized, with sometimes a complete dissolution of the MZ38,39. 
Accordingly, several studies have found a reduction of peripheral MZ-like B cells in patients with malaria40–42, 
which could explain the reduction in the IgM response in children with higher malaria exposure43 that may affect 
IgM response to α-Gal. However, in spite of the higher anti-α-Gal IgM response observed in the lower MTI site, 
the multivariable analysis showed that recent/current exposure to Plasmodium was positively associated to the 
levels of anti-α-Gal IgM, implying that malaria infection in fact induces IgM against α-Gal. These models also 
showed a negative effect of maternally transferred P. falciparum IgGs on the anti-α-Gal IgG and IgM responses 
in the offspring, suggesting an interference with anti-α-Gal antibody induction in children. A negative effect of 
maternal antibodies has been reported in the context of immune responses to vaccines44.
Third, we investigated the role of α-Gal antibodies in malaria risk or protection. Remarkably, anti-α-Gal IgM 
levels were higher in infants who did not subsequently develop any episode of malaria. Interestingly, this associ-
ation was only observed in Manhiça in site-stratified analysis. The fact that this association was only observed in 
infants but not in children contrasts with the results by Yilmaz et al., where anti-α-Gal IgMs were associated to 
protection in Malian children >4 years old17. Disparity may result from several differences between the studies: 
(i) different samples sizes (195 in our study vs 695 in Mali study); (ii) separate countries with different levels of 
α-Gal exposure due to malaria and other pathogens; (iii) different follow up times (12 months in our study vs 6 
months in Mali); (iv) different age ranges of subjects (1.5 to 17 months in our study vs 4 to 25 years in Mali); and, 
specially, due to the different ways to detect and define clinical malaria (passive case detection [PCD] defined by 
fever with any parasitemia in our study vs active case detection defined by fever with parasitemia ≥2500 para-
sites/mL in the Mali study).
Unlike IgM, anti-α-Gal IgG levels were associated with a higher risk of malaria in children, which suggests 
that a higher exposure to other pathogenic microbes containing α-Gal may increase the risk of a future malaria 
episode by, for example, deviating the immune response and/or causing a worst clinical outcome in co-infection. 
This result contrasts with the recent observation by Cabezas-Cruz et al. of a positive correlation of anti-α-Gal IgM 
and IgG with the lack of Plasmodium infection in individuals from Senegal45. However disparity of results may 
also be due to differences between the study site, age of participants and the study design.
We also investigated for the first time IgG1–4 subclass responses to α-Gal and observed new associations 
between certain subclasses and malaria protection. Interestingly, the pattern of IgG1–4 subclasses to α-Gal showed 
predominance of IgG1 and IgG2, followed by IgG3 and IgG4. This is different to the pattern against P. falci-
parum proteins, where IgG1 and IgG3 predominate and IgG2 and IgG4 are induced at much lower levels. Higher 
α-Gal IgG3 and IgG4 levels may correlate with malaria protection in children, also contrasting to what has been 
observed against protein antigens. Previous studies consistently show that cytophilic antibodies (IgG1 and IgG3) 
to protein antigens correlate more often with protection from malaria disease46–50. However, this may be differ-
ent for glycan antigens. For example, IgG4 responses predominate against Schistosoma mansoni51 with many 
antigenic glycans on its surface52, and this subclass is associated with protection against S. haematobium53. IgG4 
has been shown to be a blocking and tolerance-inducing “anti-allergenic” antibody54,55. Therefore its protective 
Figure 4. Anti-α-Gal antibody levels in Manhiça (Mozambique, low MTI) vs Kintampo (Ghana, high MTI). 
(A) Infants and children together. (B) Stratified by age group. Data correspond to samples collected at baseline 
(M0) from participants in the RTS,S phase 3 clinical trial. Boxplots represent the median and interquartile 
range. Groups were compared through t-tests and p-values were adjusted for multiple comparisons through 
Benjamini-Hochberg and Holm (in parenthesis). Infant: 1.5–3 months; Children: 5–17 months.
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effect could be mediated through a tolerogenic response to the Plasmodium infection. However, IgG3 and IgG4 
associations to malaria protection were lost in multivariable analysis and further studies with larger samples sizes 
are needed to better address this potential protective effect.
The study had some limitations, mostly related to the fact that it was performed with samples from the RTS,S 
clinical trial consisting on two age cohorts, forcing some design issues, e.g., the age range and the vaccination. 
Second, the unfeasibility to determine the exposure to other sources of α-Gal besides malaria, including other 
pathogens, commensal bacteria or food, which would have been helpful to understand why anti-α-Gal responses 
were higher in one site vs the other. Nevertheless, the fact the children from high MTI settings showed signifi-
cantly lower levels of anti-α-Gal IgG and IgM compared to children living in lower MTI settings, might be a sign 
of an underlying impairment of the immune response to polysaccharide antigens in the context of high MTI. 
These data along with the observed reduction of MZ-like B cells in chronically exposed individuals40–42, the docu-
mented deficient antibody response to polysaccharide vaccines in children with malaria35 and the higher suscep-
tibility of these children to invasive bacterial infections by polysaccharide encapsulated bacteria (as non-typhoid 
salmonella and S. pneumoniae)56,57, warrant further investigation.
Conclusions
Age and site affect the magnitude of anti-α-Gal IgM and IgG responses in African children. Levels of α-Gal IgG3, 
IgG4 and, particularly, IgM are associated with protection against clinical malaria, while total IgG levels correlate 
with malaria risk, supporting further investigations of α-Gal as a promising antigen target for future malaria 
vaccines.
Figure 5. Anti-α-Gal antibody levels in cases (malaria) vs controls (no malaria). (A) Infants and children from 
both sites together. (B) Stratified by age group. (C) Stratified by site. Data correspond to samples collected at 
M3 (after the third vaccine dose and prior the 12 months of follow up) from children participants in the RTS,S 
phase 3 clinical trial. Cases were defined as children with at least one episode of clinical malaria during the 12 
months of follow up. Boxplots represent the median and interquartile range. Groups were compared through 
t-tests and p-values were adjusted for multiple comparisons through Benjamini-Hochberg and Holm (in 
parenthesis). Infant: 1.5–3 months; Children: 5–17 months.
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Antibody
Antibody 
levels
Age 
cohort Sex Site WAZ HAZ Hb
Exposure 
index
Maternal 
antibodies
Prior 
episode† Seasonǂ Vaccine
IgG at 
M0
IgM at 
M0
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
All participants together
IgG 0.83 (0.55; 1.24) 0.74
0.74 (0.38; 
1.42) 1
1.24 (0.7; 
2.19) 1
0.1 (0.05; 
0.19) 
<0.001
0.73 
(0.55; 
0.95) 
0.059
0.75 (0.57; 
0.96) 0.1
0.91 (0.74; 
1.11) 1
1.18 (1.09; 
1.28) 
<0.001
1.39 (1.22; 
1.61) 
<0.001
4.55 (1.69; 
14.5) 0.01
0.66 (0.17; 
2.26) 1
0.64 
(0.35; 
1.16) 0.7
0.7 (0.38; 
1.28) 1
0.8 (0.56; 
1.13) 1
IgG1 0.74 (0.49; 1.1) 0.41
0.78 (0.43; 
1.43) 1
1.26 (0.71; 
2.23) 1
0.1 (0.05; 
0.19) 
<0.001
0.73 
(0.56; 
0.95) 
0.059
0.74 (0.57; 
0.96) 0.1
0.9 (0.73; 
1.11) 1
1.17 (1.08; 
1.27) 
<0.001
1.39 (1.22; 
1.6) 
<0.001
4.38 (1.62;  
13.95) 
0.01
0.68 (0.17; 
2.36) 1
0.6 (0.33; 
1.1) 0.61
0.8 (0.49; 
1.29) 1
0.83 (0.6; 
1.14) 1
IgG2 1.01 (0.65; 1.57) 0.95
0.79 (0.42; 
1.48) 1
1.48 (0.82; 
2.7) 1
0.1 (0.05; 
0.2) 
<0.001
0.7 (0.52; 
0.92) 
0.047
0.73 (0.55; 
0.94) 0.09
0.89 (0.72; 
1.09) 1
1.16 (1.07; 
1.26) 
<0.001
1.39 (1.22; 
1.61) 
<0.001
3.8 (1.38; 
12.25) 
0.02
0.49 (0.1; 
1.82) 1
0.66 
(0.35; 
1.23) 0.7
0.71 
(0.39; 
1.26) 1
0.84 (0.6; 
1.16) 1
IgG3
0.02 (0; 
0.18) 
<0.001
1.34 (0.69; 
2.65) 1
1.24 (0.69; 
2.24) 1
0.12 
(0.06; 
0.23) 
<0.001
0.71 
(0.52; 
0.93) 
0.059
0.76 (0.58; 
0.99) 0.1
0.87 (0.7; 
1.08) 1
1.18 (1.09; 
1.28) 
<0.001
1.34 (1.18; 
1.55) 
<0.001
3.97 (1.44; 
13.02) 
0.02
0.57 (0.14; 
2) 1
0.64 
(0.34; 
1.19) 0.7
0.87 
(0.54; 
1.4) 1
1.03 
(0.73; 
1.45) 1
IgG4 0.02 (0; 0.2) 0.001
1.21 (0.63; 
2.36) 1
1.18 (0.66; 
2.11) 1
0.11 
(0.06; 
0.22) 
<0.001
0.72 
(0.54; 
0.95) 
0.059
0.76 (0.58; 
0.98) 0.1
0.87 (0.7; 
1.07) 1
1.17 (1.09; 
1.28) 
<0.001
1.35 (1.18; 
1.56) 
<0.001
3.99 (1.44; 
13.08) 
0.02
0.53 (0.13; 
1.84) 1
0.64 
(0.34; 
1.18) 0.7
0.82 
(0.52; 
1.3) 1
1 (0.71; 
1.4) 1
IgM
0.43 (0.26; 
0.68) 
0.001
1.87 (0.86; 
4.23) 0.7
1.07 (0.59; 
1.93) 1
0.11 
(0.05; 
0.21) 
<0.001
0.65 
(0.48; 
0.86) 
0.01
0.75 (0.57; 
0.98) 0.1
0.84 (0.67; 
1.04) 0.6
1.27 (1.16; 
1.4) 
<0.001
1.32 (1.15; 
1.53) 
<0.001
4.43 (1.6; 
14.39) 
0.01
0.47 (0.12; 
1.68) 1
0.65 
(0.35; 
1.2) 0.7
0.82 
(0.51; 
1.29) 1
1.44 
(0.91; 
2.33) 0.7
Antibody 
levels Sex Site WAZ HAZ Hb
Exposure 
to 
malaria
Maternal 
antibodies
Prior 
episode† Season
ǂ vaccine IgG at M0
IgM at 
M0
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
Infants
IgG 1.04 (0.43; 2.51) 1
1.31 (0.61; 
2.81) 1
0.13 
(0.05; 
0.32) 
<0.001
0.84 
(0.58; 
1.22) 1
0.72 (0.5; 
1) 0.28
1.12 (0.81; 
1.58) 1
1.16 (1.03; 
1.33) 0.07
1.35 (1.16; 
1.61) 
<0.001
4.61 (1.09; 
31.58) 
0.22
0.53 (0.13; 
1.91) 1
0.89 (0.4; 
1.98) 1
0.98 
(0.38; 
2.53) 1
0.69 
(0.36; 
1.26) 1
IgG1 0.81 (0.41; 1.52) 1
1.29 (0.61; 
2.77) 1
0.14 
(0.06; 
0.35) 
<0.001
0.84 
(0.57; 
1.21) 1
0.72 (0.5; 
1) 0.28
1.11 (0.79; 
1.57) 1
1.16 (1.03; 
1.33) 0.07
1.35 (1.15; 
1.61) 
<0.001
4.45 (1.04; 
30.73) 
0.22
0.58 (0.14; 
2.08) 1
0.86 
(0.38; 
1.92) 1
0.99 
(0.47; 
2.1) 1
0.68 
(0.36; 
1.26) 1
IgG2 1.65 (0.68; 4.17) 1
1.83 (0.82; 
4.15) 0.83
0.15 
(0.06; 
0.38) 
<0.001
0.77 
(0.52; 
1.13) 
0.92
0.71 (0.49; 
1) 0.28
1.06 (0.76; 
1.51) 1
1.16 (1.03; 
1.34) 0.07
1.38 (1.17; 
1.66) 
<0.001
3.19 (0.67; 
22.94) 
0.22
0.37 (0.07; 
1.46) 0.95
0.91 
(0.39; 
2.13) 1
1.01 
(0.42; 
2.41) 1
0.74 
(0.37; 
1.44) 1
IgG3 0.01 (0; 13.86) 1
1.41 (0.65; 
3.06) 1
0.15 
(0.06; 
0.36) 
<0.001
0.84 
(0.57; 
1.22) 1
0.74 (0.52; 
1.03) 0.28
1.09 (0.78; 
1.54) 1
1.16 (1.03; 
1.33) 0.07
1.35 (1.15; 
1.59) 
<0.001
4.39 (1.03; 
30.19) 
0.22
0.64 (0.15; 
2.36) 1
0.94 
(0.42; 
2.1) 1
1.07 (0.5; 
2.28) 1
0.68 
(0.36; 
1.24) 1
IgG4 0.09 (0; 4636.2) 1
1.28 (0.6; 
2.75) 1
0.14 
(0.05; 
0.34) 
<0.001
0.83 
(0.56; 
1.2) 1
0.72 (0.51; 
1) 0.28
1.12 (0.8; 
1.58) 1
1.16 (1.03; 
1.33) 0.07
1.37 (1.16; 
1.63) 
<0.001
4.58 (1.06; 
31.87) 
0.22
0.55 (0.14; 
1.96) 1
0.92 
(0.41; 
2.04) 1
1.01 
(0.48; 
2.13) 1
0.69 
(0.36; 
1.29) 1
IgM
0.24 (0.1; 
0.52) 
<0.001
0.87 (0.37; 
1.98) 1
0.22 
(0.08; 
0.57) 
0.002
0.74 
(0.48; 
1.1) 0.82
0.71 (0.48; 
1.01) 0.28
1.02 (0.71; 
1.46) 1
1.24 (1.08; 
1.44) 
0.009
1.26 (1.07; 
1.5) 0.006
3.63 (0.79; 
26) 0.22
0.54 (0.13; 
2.02) 1
1.04 
(0.44; 
2.46) 1
1.25 
(0.56; 
2.82) 1
1.08 
(0.54; 
2.23) 1
Antibody 
levels Sex Site WAS HAZ Hb
Exposure 
to malaria
Maternal 
antibodies
Prior 
episode† vaccine
IgG at 
M0
IgM at 
M0
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
Children
IgG 0.88 (0.5; 1.53) 1
1.16 
(0.49; 
2.78) 1
0.02 (0; 
0.09) 
<0.001
0.59 (0.38; 
0.88) 
0.043
0.79 (0.52; 
1.18) 1
0.71 (0.52; 
0.96) 0.14
1.29 (1.14; 
1.49) 
<0.001
1.6 (1.21; 
2.31) 
0.001
4.78 (1.26; 
23.32) 
0.12
0.4 (0.16; 
1) 0.25
0.23 
(0.07; 
0.7) 0.05
1.27 
(0.41; 
4.09) 1
IgG1 0.76 (0.42; 1.32) 1
1.18 (0.5;
2.84) 1
0.03 
(0.01; 
0.11) 
<0.001
0.6 (0.38; 
0.89) 
0.043
0.79 (0.52; 
1.17) 1
0.73 (0.53; 
0.97) 0.15
1.29 (1.14; 
1.49) 
<0.001
1.6 (1.22; 
2.31) 
0.001
4.89 (1.28; 
24.2) 0.12
0.39 
(0.15; 
0.98) 
0.25
0.55 
(0.24; 
1.19) 0.5
1.25 
(0.45; 
3.62) 1
IgG2 0.91 (0.52; 1.57) 1
1.09 
(0.44; 
2.72) 1
0.04 
(0.01; 
0.12) 
<0.001
0.59 (0.37; 
0.9) 0.043
0.75 (0.48; 
1.13) 1
0.73 (0.53; 
0.97) 0.15
1.28 (1.13; 
1.49) 
<0.001
1.54 (1.18; 
2.22) 
0.002
4.34 (1.13; 
21.36) 
0.12
0.39 
(0.15; 
1) 0.25
0.46 
(0.18; 
1.11) 
0.42
1.31 
(0.44; 
4.03) 1
Continued
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Materials and Methods
Subjects and samples. Samples from African children participating in RTS,S/AS0 clinical trials were 
included in this analysis. First, a pilot study to assess age patterns of anti-α-Gal antibody immunogenicity in 
individuals age <5 years old was performed with serum samples from 104 Mozambican children of two cohorts 
exposed to different levels of MTI (Manhiça - low MTI, and Ilha Josina - high MTI), vaccinated with RTS,S/AS02 
within a phase 2b trial58. This pilot was carried out to set up the α-Gal antibody assay and to confirm the age 
pattern of response previously described in Malian children17. A second larger study was performed to assess IgG 
subclasses and association between anti-α-Gal antibodies and malaria protection, and factors affecting it. This 
analysis included plasma and serum samples from 195 subjects enrolled in the RTS,S/AS01 phase 3 trial59 from 
two younger age groups (1.5–3 months [infants] and 5–17 months [children]), and two different African sites 
(Manhiça-Mozambique [low MTI] and Kintampo-Ghana [moderate-high MTI]), having 131 RTS,S-vaccinees 
and 66 comparator-vaccinees.
In both studies, samples were collected at the first study visit (recruitment, coinciding with baseline before 
vaccination, M0) and the second study timepoint three months later (M3, after three doses of vaccination). For 
the detection of clinical malaria cases (fever >37.5 °C with any parasitaemia), children were followed up by PCD 
starting 14 days after sample collection at M3 for the subsequent 12 months.
Antibody Luminex assay. Antibodies against α-Gal (Galα1-3 Galβ1-4GlcNAc-R-BSA, Dextra NGP0334) 
were measured by quantitative suspension array technology (qSAT) using the Luminex xMAP™ technology 
Antibody
Antibody 
levels
Age 
cohort Sex Site WAZ HAZ Hb
Exposure 
index
Maternal 
antibodies
Prior 
episode† Seasonǂ Vaccine
IgG at 
M0
IgM at 
M0
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
OR (CI) 
P-val
IgG3
0.02 (0; 
0.18) 
0.002
1.11 
(0.44; 
2.8) 1
0.04 
(0.01; 
0.15) 
<0.001
0.56 (0.34; 
0.88) 
0.043
0.78 (0.51; 
1.19) 1
0.74 (0.53; 
1) 0.15
1.24 (1.1; 
1.44) 
<0.001
1.51 (1.13; 
2.26) 
0.007
3.41 (0.83; 
17.99) 
0.15
0.36 
(0.13; 
0.97) 
0.25
0.78 
(0.42; 
1.46) 
0.61
1.44 
(0.49; 
4.49) 1
IgG4
0.01 (0; 
0.18) 
0.003
1.06 
(0.42;  
2.66) 1
0.05 
(0.01; 
0.16) 
<0.001
0.61 (0.38; 
0.93) 
0.043
0.81 (0.53; 
1.22) 1
0.72 (0.51; 
0.97) 0.15
1.25 (1.1; 
1.45) 
<0.001
1.5 (1.11; 
2.25) 
0.007
3.65 (0.88; 
19.45) 
0.15
0.36 
(0.13; 
0.97) 
0.25
0.73 (0.4; 
1.32) 
0.61
1.25 
(0.45; 
3.64) 1
IgM 0.55 (0.16; 1.82) 1
1.18 (0.5; 
2.84) 1
0.04 
(0.01; 
0.13) 
<0.001
0.58 (0.36; 
0.86) 
0.041
0.79 (0.52; 
1.17) 1
0.73 (0.53; 
0.97) 0.15
1.29 (1.14; 
1.49) 
<0.001
1.72 (1.26; 
2.62) 
<0.001
4.54 (1.19; 
22.19) 
0.12
0.4 (0.15; 
0.99) 
0.25
0.64 
(0.35; 
1.13) 0.5
1.68 
(0.51; 
6.44) 1
Table 5. Factors associated with risk of clinical malaria in univariate logistic regression models, showing odds 
ratios (OR) and 95% confidence intervals (CI). Data from the phase 3 trial participants, including anti-α-Gal 
antibody data at M3 and covariates. The analysis was performed for all participants together and stratifying by 
age group (infants and children). Results show those factors that affect the risk of clinical malaria when anti-
α-Gal antibodies are taken into account. P-values were adjusted for multiple comparisons through Benjamini-
Hochberg and Holm, those significant are in bold. Age cohort (children vs infants). Sex (male vs female). 
Site (Manhiça vs Kintampo). WAZ (Weight-for-Age Z-score). HAZ (Height-for-Age Z-score). Hb (Baseline 
hemoglobin (g/dL). Exposure index (baseline anti-P. falciparum exposure IgM levels). Maternal index (baseline 
maternally transferred antibodies). †Malaria episode between month 0 and month 3 (yes vs no). ǂMalaria 
transmission season at month 3 sample collection (low vs high). Vaccine (RTS,S vs comparator).
Antibody
All subjects together Infants Children
OR (CI) p-val Covariates* OR (CI) p-val Covariates* OR (CI) p-val Covariates*
IgG 1.86 (1;3.5) 0.051 Age, site, exposure Site, exposure 7.99 (1.54;58.03) 0.02 Site, vaccine
IgG1 Age, site, exposure Site, exposure Site, vaccine
IgG2 Age, site, exposure Site, exposure Site, vaccine
IgG3 Age, site, exposure Site, exposure Site, vaccine
IgG4 Age, site, exposure Site, exposure Site, vaccine
IgM 0.38 (0.2;0.71) 0.003 Site, exposure 0.29 (0.1;0.77) 0.02 Site, exposure Site, vaccine
Table 6. Association between anti-α-Gal antibody levels and risk of clinical malaria in multivariable logistic 
regression models. Data from phase 3 trial including all individuals together and stratified by age group, 
fitted including anti-α-Gal antibody data at M3 and adjusting by significant variables in univariate models 
to remove potential cofounding effects in the associations. P-values were adjusted for multiple comparisons. 
Data presented correspond to variables that were statistically significant. *Covariates that in the multivariable 
analyses (backward and forward stepwise algorithms combined to obtain the model with the minimum akaike 
information criterion) were statistically significant. Age (Infants vs children); Site (Manhiça vs Kintampo); 
Exposure (malaria exposure antibody index); Vaccine (RTS,S vs comparator).
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(Luminex Corp., Austin, Texas). α-Gal was covalently coupled to MagPlex beads and these were blocked with 
BSA. α-Gal-coupled beads were added to 96-well μClear® flat bottom plates (Greiner Bio-One) (1,000 micro-
spheres/well) resuspended in 50 µL of PBS, 1% BSA, 0.05% Azide pH 7.4 (PBS-BN). The multiplex antigens 
panel also contained beads coupled to 32 P. falciparum protein constructs based on pre-erythrocytic (SSP2/
TRAP, CelTOS, LSA-1, EXP-1) and erythrocytic (AMA-1, EBA-140, EBA-175, MSP-1, MSP-2, MSP-3, MSP-5, 
MSP-6, CyRPA, P41, PfRh1, PfRh2, PfRh4, var2csa) stage antigens analyzed as markers of malaria exposure and 
maternally-transferred antibodies.
Fifty µL of sample, positive control (serial dilutions of the WHO reference reagent for anti-malaria human 
serum NIBSC code 10/198 for the IgG assays; or a pool of samples with high IgM levels against P. falciparum for 
the IgM assay)60, negative control (individual plasma samples from malaria naïve Spanish adults) or PBS-BN 
(Blanks) were added to the wells and incubated with the beads at 4 °C overnight (ON) in a shaker protected 
from light. Plates were washed three times with 200 µL/well of PBS-Tween 20 0.05% using a manual magnetic 
washer. 100 µL of biotinylated secondary antibody were added diluted in PBS-BN as described61: anti-human 
IgG (Sigma), anti-human IgM (Sigma), anti-human IgG1 (Abcam) and anti-human IgG3 (Sigma). For IgG2 
and IgG4 assays, secondary antibodies added were unconjugated mouse anti-human IgG4 (Thermo Fisher) and 
mouse anti-human IgG2 (Thermo Fisher), respectively, followed by biotinylated goat anti-mouse IgG (Sigma) 
in PBS-BN. All antibody incubations were performed at room temperature (RT) for 60 min, in agitation and 
protected from light. Next, 100 µL of streptavidin-R-phycoerythrin (Sigma) in PBS-BN were added to all wells 
and incubated 30 min, at RT, in agitation and protected from light. Plates were washed as before and beads were 
resuspended in 100 μL/well of PBS-BN. Plates were covered protected from light and stored at 4 °C ON to be read 
the next day using the Luminex xMAP® 100/200 analyser, and at least 50 microspheres per analyte were acquired 
per sample.
Test samples were assayed at 4 dilutions for IgG (500, 5000, 50,000 and 500,000), IgG1, IgG3 (100, 1000, 10,000 
and 100,000) and IgM (100, 1000, 10,000 and 50,000), and 2 dilutions for IgG2 and IgG4 (50 and 500) to ensure 
that at least one dilution lie in the linear range of the respective standard curve. For IgG assays, 18 to 22 serial 
dilutions (1:2) of the positive control starting at 1:50 were used to perform subclass-specific standard curves. For 
the IgM assay, 18 serial dilutions (1:2) of a pool of samples from ISGlobal repository with high IgM levels against 
P. falciparum antigens were used. Blanks were added to each plate in triplicates for quality control purposes. 
Sample distribution across plates was designed ensuring a balanced distribution of site, age cohort and malaria 
cases. Data were captured using xPonent software, and antibody levels were measured as median fluorescence 
intensity (MFI).
Data analysis. Preprocessing. To stabilize the variance, the analysis was done on log10-transformed values of 
the MFI measurements. The positive control standard curve for each isotype/subclass-plate was estimated using 
the drLumi R package flow62. Standard curves were fitted in a 5-parameter logistic (5-PL) regression model, and 
data points were weighted by logarithmic variance. If the model did not converge, 4-PL or exponential regressions 
were fitted. The quality control for each plate was based on the estimation of the % coefficient of variation (CV) 
of the 3 blank controls. Blanks were also used to establish the antigen-isotype/subclass specific lower limits of 
quantification (LLOQ) and lower limits of detection (LLOD) calculated as the blanks mean +10 SD and blanks 
mean +3 SD, respectively63. The characteristics of the standard curves were visually inspected for quality control 
purposes. To select the sample working dilution (isotype/subclass and plate specific), an algorithm that detects 
the two points with the highest slope between them in the positive control sigmoidal curve was used. The slope 
was computed as:
=
−
−
+
+
m
log MFI log MFI
dilution factor dilution factor
10( ) 10( )
_ _
i i
i i
1
1
The mean log10 MFI value of the two points was computed, and the nearest log10 MFI of the test sample and the 
corresponding dilution was selected. For IgG2 and IgG4 assays standard curves did not converge, then the first 
sample dilution was assigned. The log10 MFI of the selected dilution was corrected multiplying by its correspond-
ing dilution factor. Blank background signal was not subtracted.
Statistical analysis. Descriptive comparisons of antibody levels between age groups, time points and sites were 
done by trajectory plots, boxplots representing the median and interquartile range (analyzed by t-tests), and 
dotplots with bars corresponding to the geometric mean and confidence intervals (CI) (analyzed by the Mann 
Whitney t-test). The effect of age was also evaluated through scatterplots and regression models and assessing its 
interaction with site.
The analysis of factors affecting levels of anti-α-Gal Ig at M3 was performed using data from children partici-
pating in the RTS,S phase 3 trial and applying multivariable linear regression models (Coefficient, 95% CI, p val-
ues). The predictors assessed were: age as continuous variable (weeks), age cohort (children vs infants), sex (male 
vs female), site (Manhiça vs Kintampo), baseline weight for age Z score (WAZ) and height for age Z score (HAZ), 
baseline hemoglobin levels (Hb), malaria episodes prior to M3 (yes vs no), malaria transmission season (low vs 
high), vaccination (RTS,S vs comparator), baseline α-Gal IgG levels, baseline α-Gal IgM levels, level of malaria 
exposure and maternally-transferred malaria antibodies. To define a P. falciparum exposure index, we selected 28 
protein antigens in which IgM responses were M3 > M0 and thus acquired with age (e.g. children > infants) and 
exposure (e.g. Kintampo > Manhiça) (data not shown). Principal component analysis (PCA) was performed to 
construct the corresponding variables, and the first component (PC1) that explained 63% of the variability was 
selected to be used as a variable in the models. To define a P. falciparum maternal antibody index in subjects <10 
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months of age, we selected 17 antigens including two VAR2CSA pregnancy-specific antigen constructs which IgG 
responses were M0 > M3 and thus declined with age (e.g. infants > children) and were higher in infants from the 
high MTI site (e.g. Kintampo > Manhiça) (data not shown). We selected the first component that explained 54% 
of the variability and used that as a variable in the models.
The analysis of the association between anti-α-Gal antibody levels and clinical malaria was based on a 
case-control design. Univariate logistic regression models (odds ratio [OR], 95% CI, p values) with α-Gal anti-
body data at M3 as main predictor, including other covariates (same as above) and their interactions, were fitted 
to identify factors that affected malaria risk when α-Gal antibodies were taken into account. Covariates that were 
significant in the univariate models were included in the stepwise (forward and backward) multivariable models 
to remove potential cofounding effects. P-values were adjusted for multiple testing through Benjamini-Hochberg 
or Holm, depending on the analysis. None of the interactions were significant after adjusting for multiple com-
parisons, therefore they are not reported in the tables. All models were also performed stratifying by age group, 
by site, and by age and site at the same time. Significance was defined at the p < 0.05 level and analyses were 
performed with R.
Data availability. All data generated or analyzed during this study are included in this published article (and 
its Supplementary Information files).
Ethics Statement. All methods were performed in accordance with the relevant guidelines and regulations. 
Approval for the study protocol was obtained from the Ethical Committee of the Hospital Clínic in Barcelona 
(CEIC, Spain), the National Health and Bioethics Committee (CNBS, Mozambique), and the Ghana Health 
Service Ethical Review Committee (GHSERC, Ghana). Written informed consent was obtained from parents or 
guardians of participating children in accordance with the Declaration of Helsinki.
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